Clinical Trial Update: Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating weekly docetaxel plus irinotecan in patients with non-resectable gastric cancer after cisplatin plus 5-FU/leucovorin has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED